Concentration is not a dose
The listed concentration is 3 mg/mL. Follow only your prescription’s route, dose, and schedule; this page provides no dosing or syringe-unit conversion instructions.
TB-500 · 3 mg/mL3 mg/mL injection.
An informed conversation.
Discuss TB-500 with a licensed clinician, including the limited human evidence, potential risks, and whether any treatment is appropriate for your needs.
Prescription only; clinical approval and pharmacy availability required. An evaluation does not guarantee a prescription. TB-500 is not FDA-approved.
Important safety & evidence informationUNDERSTAND THE EVIDENCE
TB-500 is investigational. Benefits for injury healing or recovery are not established in people.
In FDA’s review, TB-500 denotes a seven-amino-acid fragment of thymosin beta-4, distinct from the full-length molecule.
FDA’s 2026 evaluation did not identify human clinical studies of TB-500. Your pharmacy must confirm the ingredient and salt form.
Evidence and identity background: FDA TB-500 scientific review (PDF).
HOW IT WORKS
A medical evaluation starts a conversation. It does not establish eligibility or make treatment automatic.

Complete the peptides intake with your health history, symptoms, current medications, and goals. Tell the clinician about previous treatments and any questions about TB-500.

A licensed clinician reviews your information, discusses uncertainties and alternatives, and decides whether any prescription is appropriate. Further information or an in-person assessment may be needed.

If prescribed, review the pharmacy label, instructions, monitoring, and follow-up with your care team. Ask questions before using a medication or changing treatment.
BEFORE YOU BEGIN
The clinician and dispensing pharmacist confirm the details of your own prescription.
The listed concentration is 3 mg/mL. Follow only your prescription’s route, dose, and schedule; this page provides no dosing or syringe-unit conversion instructions.
Use the directions supplied with your exact formulation. Confirm its storage requirements, expiration or beyond-use date, and handling instructions with the pharmacy. Do not substitute another product’s instructions.
Monthly billing is $199; quarterly billing is $459 every 3 months. A billing interval is not a recommendation for a treatment duration. Review quantities, inclusions, renewals, and cancellation terms during enrollment.
A product listing is not a guarantee of prescribing or dispensing in your state. Review our Compliance page, Cancellation Policy, and Refund Policy.
READ BEFORE CONSIDERING TREATMENT
TB-500’s safety in people is not established. Discuss individual risks with your clinician.
Compounded TB-500 has not undergone FDA premarket review for safety, effectiveness, or quality. The current HHS interim policy describes conditional enforcement discretion for certain TB-500 acetate injectable preparations. It is not drug approval or proof of safety. Your clinician and pharmacy must verify ingredient identity, the prescribed route, and all applicable conditions for the specific preparation.
Read the HHS interim policy (PDF), TB-500 sectionLIMITED HUMAN SAFETY INFORMATION
FDA highlights potential immune-response risks involving aggregation and impurities. Human safety data are inadequate; adverse-effect frequencies are unknown.
Tell your clinician about medical conditions, allergies, current medicines, supplements, and previous reactions. Discuss pregnancy, pregnancy plans, or breastfeeding before considering treatment. Ask about established alternatives for your concerns.
Contact your care team promptly about new or concerning symptoms. Seek urgent medical care for breathing difficulty, face or throat swelling, or other signs of a serious allergic reaction. Call 911 for a medical emergency.
TB-500 is prohibited in and out of competition under section S2.3 of the 2026 WADA Prohibited List. A prescription does not automatically establish permission under anti-doping rules. Check with your sport’s anti-doping organization before considering it.
Sources checked November 12, 2026: FDA TB-500 scientific review (PDF), HHS interim policy (PDF), and WADA 2026 list (PDF). Requirements may change; the care team must verify current conditions.
TB-500 3 mg/mL injection is $199 per month with monthly billing, or $459 per quarter, billed every 3 months. The quarterly option is equivalent to $153 per month. Confirm quantities, inclusions, and terms during enrollment.
No. TB-500 is not FDA-approved. A prescription or conditional compounding policy does not change that status. Review the safety and compounding information above.
No. The FDA-reviewed TB-500 fragment and full-length thymosin beta-4 are distinct. Your pharmacy must verify the ingredient supplied.
Those benefits are not established by adequate human evidence. Discuss your symptoms and established care options with a licensed clinician.
It is the concentration: the amount in each milliliter. It does not state your dose, frequency, package volume, or total quantity. Your clinician and pharmacist confirm your exact prescription and directions.
The 2026 WADA list prohibits TB-500 at all times under S2.3. Athletes subject to anti-doping rules should consult their anti-doping organization; a prescription is not automatic permission.
No. It describes the billing interval. Your clinician determines any treatment plan, monitoring, and follow-up. Confirm quantities and terms before enrollment; an evaluation does not guarantee a prescription.
YOUR NEXT STEP
Share your health history and questions with a licensed clinician.
Prescription only. Subject to clinical approval.